The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis

Human Pathology

Volumn 40, Issue 3, 2009, Pages 356-365

  Gupta, Ruta ^a   Dastane, Aditi M ^a   McKenna Jr , Robert ^b   Marchevsky, Alberto M ^a  

^a Edars Sinai Medical Center   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Evidence based pathology; Gefitinib; Meta analysis; Pulmonary adenocarcinoma; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ARTICLE; COMPUTER PROGRAM; ETHNICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; PROTEIN ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 59049105640     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.08.008     Document Type: Article

References (50)

1. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
2. Sasaki H., Endo K., Okuda K., et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol (2007)
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33 (2006) 369-385
5. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
6. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
7. Ohsaki Y., Tanno S., Fujita Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7 (2000) 603-607
8. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
9. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
10. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
11. Han S.W., Kim T.Y., Hwang P.G., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
12. Hirsch F.R., Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
13. Chang A., Parikh P., Thongprasert S., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1 (2006) 847-855
14. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
15. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
16. Parra H.S., Cavina R., Latteri F., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
17. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
18. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
19. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23 (2005) 6838-6845
20. Marchevsky A.M. Evidence-based medicine in pathology: an introduction. Semin Diagn Pathol 22 (2005) 105-115
21. Marchevsky A.M., and Wick M.R. Evidence-based medicine, medical decision analysis, and pathology. Hum Pathol 35 (2004) 1179-1188
22. Egger M., Smith G.D., and Sterne J.A. Meta-analysis: is moving the goal post the answer?. Lancet 351 (1998) 1517
23. Egger M., Smith G.D., and Sterne J.A. Uses and abuses of meta-analysis. Clin Med 1 (2001) 478-484
24. Sterne J.A., Egger M., and Smith G.D. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 323 (2001) 101-105
25. Petrisor B.A., Keating J., and Schemitsch E. Grading the evidence: levels of evidence and grades of recommendation. Injury 37 (2006) 321-327
26. Baujat B., Mahe C., Pignon J.P., and Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med 21 (2002) 2641-2652
27. Macaskill P., Walter S.D., and Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 20 (2001) 641-654
28. Pugh T.J., Bebb G., Barclay L., et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer 7 (2007) 128
29. Cappuzzo F., Ligorio C., Janne P.A., et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25 (2007) 2248-2255
30. Ichihara S., Toyooka S., Fujiwara Y., et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120 (2007) 1239-1247
31. Dziadziuszko R., Witta S.E., Cappuzzo F., et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res 12 (2006) 3078-3084
32. Sone T., Kasahara K., Kimura H., et al. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer 109 (2007) 1836-1844
33. Daniele L., Macri L., Schena M., et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 6 (2007) 1223-1229
34. Yang C.H., Shih J.Y., Chen K.C., et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer 107 (2006) 1873-1882
35. Han S.W., Kim T.Y., Jeon Y.K., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12 (2006) 2538-2544
36. Argiris A., Hensing T., Yeldandi A., et al. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol 1 (2006) 52-60
37. Kimura H., Kasahara K., Shibata K., et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 1 (2006) 260-267
38. Endo K., Sasaki H., Yano M., et al. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 16 (2006) 533-541
39. Bell D.W., Lynch T.J., Haserlat S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
40. Chou T.Y., Chiu C.H., Li L.H., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
41. Rosell R., Ichinose Y., Taron M., et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50 (2005) 25-33
42. Kakiuchi S., Daigo Y., Ishikawa N., et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 13 (2004) 3029-3043
43. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004) 13306-13311
44. Dziadziuszko R., Holm B., Skov B.G., et al. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 18 (2007) 447-452
45. Asahina H., Yamazaki K., Kinoshita I., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
46. Portera C.C., Walshe J.M., Rosing D.R., et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14 (2008) 2710-2716
47. Silvestri G.A., and Rivera M.P. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128 (2005) 3975-3984
48. Eberhard D.A., Giaccone G., and Johnson B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26 (2008) 983-994
49. Hirsch F.R., and Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17 (2005) 118-122
50. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807